OROtávio Hallal Ferreira Raro

Otávio Hallal Ferreira Raro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Otávio Hallal Ferreira Raro has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanisms of cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii: A Swiss 2023–2025 collection

    by Jaime Rodriguez-Lopez, Jacqueline Findlay, Otavio Hallal Ferreira Raro, Patrice Nordmann

  • Open Access

    Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1

    by Otávio Hallal Ferreira Raro, Stefano Mancini, Jacqueline Findlay, Helena M B Seth-Smith, Muhammad Ali Syed, Adrian Egli, Patrice Nordmann, Laurent Poirel

    Background: The class C β-lactamase, PAC-1, was originally described as acquired in Pseudomonas aeruginosa clinical isolates from south Asia, the corresponding gene being chromosomally located and embedded within a Tn1721-like transposon. Despite its association with high-level resistance to cephalosporins and β-lactam/β-lactamase inhibitor combinations, data on its full hydrolytic profile and kinetic parameters have not yet been comprehensively characterized. Objectives: To characterize the susceptibility profile and hydrolytic kinetics of PAC-1, with a particular focus on cefiderocol hydrolysis, and the activity of novel β-lactam/β-lactamase inhibitor combinations. Methods: The blaPAC-1 allele was cloned into vector pUCP24 and expressed in Escherichia coli TOP10 and Pseudomonas aeruginosa PAO1, respectively. MICs were determined by broth microdilution and interpreted according to EUCAST guidelines. PAC-1 was purified, and steady-state kinetic measurements of selected β-lactams were determined. IC50 values were determined for the β-lactamase inhibitors avibactam, taniborbactam, xeruborbactam and zidebactam. WGS was performed to characterize the genetic environment of the blaPAC-1 gene. Results: PAC-1 conferred broad resistance to penicillins, broad-spectrum cephalosporins and cefiderocol, while carbapenems remained unaffected. Kinetic analyses confirmed high catalytic efficiency against cefotaxime and aztreonam, but no hydrolysis of imipenem. Avibactam, relebactam and vaborbactam failed to inhibit PAC-1 (IC50 > 1000 µM), whereas xeruborbactam and zidebactam showed potent inhibitory activities (IC50 = 1.0 and 0.6 µM, respectively). A chromosomally located Tn1721-like transposon was identified carrying the blaPAC-1 gene in P. aeruginosa ST4936. Conclusions: PAC-1 is not inhibited by avibactam and hydrolyses a broad range of β-lactams including the novel cephalosporin cefiderocol. The combination cefiderocol/zidebactam was the most active against PAC-1. Transposon-mediated dissemination across distinct lineages warrants continued epidemiological surveillance of PAC-type β-lactamases.

  • Open Access

    Beneficial impact of acquired AmpC β-lactamases on bacterial fitness and pathogenicity: a new paradigm

    by Otávio Hallal Ferreira Raro, Charlotte Michaux, Andrea Endimiani, Jorge Larios, Claudia Aldeia, Edgar I. Campos-Madueno, Jacqueline Findlay, Patrice Nordmann, Vincent Cattoir, Laurent Poirel

    AmpC-type β-lactamases share structural similarities with penicillin-binding proteins, supporting the view that both enzyme families evolved from a common ancestor. Considering the widespread dissemination of acquired AmpCs in Gram-negative bacteria, we hypothesize that, besides their established role in β-lactam resistance, they may also influence essential bacterial mechanisms. Thus, this study aimed to elucidate whether AmpCs modulate bacterial physiology and fitness. Escherichia coli MG1655 was used as the model organism to assess the impact of clinically relevant acquired AmpCs (CMY, DHA, ACC, and FOX variants) on growth, competition, motility, biofilm formation, and pathogenicity, coupled with transcriptomic profiling. We demonstrated that certain CMY variants (notably CMY-42 and CMY-145) confer an unexpected in vitro growth advantage, whereas CMY-2 enhances pathogenicity in vivo by inducing flagellar production. These findings establish a new paradigm in which some AmpCs act as both resistance determinants and regulators of bacterial fitness and virulence, contributing to the ecological success of Enterobacterales. IMPORTANCE: Although β-lactamases have always been considered enzymes involved in resistance to β-lactam antibiotics, they also have to be considered as playing a role in reshaping bacterial physiology. By studying a series of class C β-lactamases, we uncovered an unexpected dual role. Besides conferring resistance to β-lactams, they also impact bacterial growth, motility, and pathogenicity through modulation of flagellar biosynthesis. Strikingly, while CMY-42- and CMY-145-producing recombinant Escherichia coli strains showed enhanced in vitro fitness growth by reducing energy-costly flagellar production, production of CMY-2 (the most commonly identified acquired AmpC β-lactamase identified in Enterobacterales) restored flagella and increased virulence in vivo . This work reframes β-lactamases as metabolic regulators influencing ecological success, offering new insight into how resistance determinants promote the spread and clinical impact of Enterobacterales.


  • Open Access

    Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors

    by Otávio Hallal Ferreira Raro, Csaba Szabo, Patrice Nordmann

    Metallo-β-lactamase (MBL)–producing Enterobacterales represent a major public health threat because they confer resistance to all β-lactams except monobactams. The most prevalent MBLs include VIM, IMP, and NDM types, which render all clinically approved β-lactamase inhibitors ineffective. This study evaluates whether cyanide-containing molecules such as the efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP), carbonyl cyanide 4-trifluoromethoxyphenylhydrazone (FCCP) or the cytochrome C oxidase inhibitor potassium cyanide (KCN) can restore carbapenem susceptibility in MBL–producing strains by disrupting zinc-dependent enzymatic activity. A series of isogenic Escherichia coli TOP10 and MG1655 strains carrying the shuttle vector pUCP24 harbouring various MBLs and clinical strains were included in this study. The strains were subjected to antimicrobial susceptibility testing by broth microdilution, checkerboard assays, determination of the 50% inhibitory concentration (IC50) of carbapenemase activity, kinetic assays and time-kill curve assays. CCCP, FCCP and KCN restored carbapenem (imipenem) susceptibility in E. coli strains producing VIM-1–like enzymes. Synergy was observed in checkerboard assays, and reduction of bacterial growth was confirmed by time-kill experiments. The addition of Zn2+ reversed this effect, supporting a Zn2+-chelating or Zn2+-displacing mechanism. Non–VIM-1-like MBLs, including VIM-2, IMP-1 and NDM-1, were not affected by the addition of cyanide-containing compounds, indicating strong selectivity of these inhibitory effects. IC50 measurements confirmed the selective activity of CCCP, FCCP and KCN against VIM-1–like MBLs. CCCP, FCCP and KCN exhibited inhibitory activity against VIM-1–like MBLs, restoring imipenem susceptibility in E. coli at very low concentrations (0.04–19.55 µM). Thus, certain efflux pump inhibitors, as well as the gaseous biological mediator cyanide, have a novel action as inhibitors of MBL enzymatic activity, which, in turn, renders them potentially useful as adjunct antibacterial agents.

  • Open Access

    In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes

    by Otávio Hallal Ferreira Raro, Jacqueline Findlay, Laurent Poirel, Jean-Winoc Decousser, Patrice Nordmann

    Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a critical global health threat due to its high mortality rates in infections, limited treatment options and resistance to last-resort antibiotics. Cefiderocol, a novel siderophore-conjugated cephalosporin, has emerged as a promising therapeutic agent against such infections. However, resistance to this antibiotic has already been reported. Objectives: To investigate whether the production of common carbapenemases affects cefiderocol susceptibility in A. baumannii and to identify the genetic mechanisms underlying resistance development. Methods: Using isogenic A. baumannii CIP 7010 strains carrying carbapenemase genes commonly identified in that species, namely blaNDM-1, blaOXA-23, blaOXA-40 or blaOXA-58, mutants were selected under increasing cefiderocol pressure. Mutants obtained were subjected to MIC determinations, WGS, complementation assays, real-time quantitative PCR (RT-qPCR) and fitness assays. Results: WGS of cefiderocol-resistant isolates revealed recurrent mutations in genes encoding the global regulators BfmS and OxyR, rather than in genes directly related to iron uptake, PBPs or β-lactamases. Complementation assays with WT bfmRS or oxyR resulted in a reversion to the parental strain cefiderocol MICs. RT-qPCR indicated that these global regulators reduced expression of piuA and pirA genes involved in iron uptake, and hence were associated with a previously unknown mechanism that results in resistance to cefiderocol. Conclusions: Global regulators BfmS and OxyR were responsible for decreasing the expression of piuA and pirA genes, thereby contributing to cefiderocol resistance. This evolutionary analysis enhances our understanding of the mechanisms underlying cefiderocol resistance and identifies potential molecular targets for the development of new therapeutics against CRAB.


  • Open Access

    The NitroSpeed Taniborbactam NP test as a rapid test for detection of β-lactamase-mediated susceptibility to taniborbactam

    by Otávio Hallal Ferreira Raro, Soraya Herrera-Espejo, Maxime Bouvier, Auriane Kerbol, Laurent Poirel, Patrice Nordmann

    Taniborbactam (TAN) is an investigational β-lactamase inhibitor in clinical development combined with cefepime for the treatment of bacterial infections caused by broad-spectrum β-lactamase-expressing bacteria. Its spectrum of inhibition encompasses all classes of β-lactamases, including clinically important metallo-β-lactamases (MBLs) NDM-1 and VIM-2. However, TAN lacks a significant inhibition of imipenemase-type β-lactamases. Rare TAN-resistant New Delhi metallo-β-lactamase (NDM) or Verona integron-encoded metallo-β-lactamase (VIM) variants (namely NDM-9, NDM-30, and VIM-83) have been identified. The NitroSpeed Taniborbactam NP test was developed to rapidly assess the β-lactamase inhibitory activity of TAN against various β-lactamases, particularly serving as an efficient tool for identifying compounds with potential activity against different types of MBLs. The test is based on the hydrolysis of (i) nitrocefin (to determine the presence or absence of β-lactamase), (ii) ertapenem (to confirm the presence or the absence of carbapenemase), and (iii) TAN (to assess whether the carbapenemase is inhibited by TAN). The test was validated using a collection of 134 genetically characterized clinical isolates (103 Enterobacterales and 31 Pseudomonas aeruginosa). The NitroSpeed Taniborbactam NP test is simple, easy to perform, and provides results within ≤15 min. When evaluated against a broad set of β-lactamases, the test demonstrated 100% sensitivity, specificity, and accuracy.

  • Open Access

    In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates

    by Christophe Le Terrier, Otávio Hallal Ferreira Raro, Alaaeldin Mohamed Saad, Patrice Nordmann, Laurent Poirel

    Purpose: Overproduction of the intrinsic chromosomally-encoded AmpC β-lactamase is one of the main mechanisms responsible for broad-spectrum β-lactam resistance in Pseudomonas aeruginosa. Our study aimed to evaluate the in-vitro activity of anti-pseudomonal β-lactam molecules associated with the recently-developed and commercially-available β-lactamase inhibitors, namely avibactam, relebactam and vaborbactam, against P. aeruginosa isolates overproducing their AmpC. Methods: MIC values of ceftazidime, cefepime, meropenem, imipenem and ceftolozane with or without β-lactam inhibitor were determined for 50 AmpC-overproducing P. aeruginosa clinical isolates. MIC breakpoints for resistance were retained at 8 mg/L for β-lactams and β-lactam/β-lactamase inhibitor combinations containing ceftazidime, cefepime and meropenem, while 4 mg/L was used for those containing imipenem and ceftolozane. The concentration of all β-lactamases inhibitors was fixed at 4 mg/L, except for vaborbactam (8 mg/L). Results: The rates of isolates not being resistant to ceftazidime, cefepime, meropenem, imipenem and ceftolozane were found at 12%, 22%, 34%, 8% and 74%, respectively. When combined with avibactam, those rates increased to 60%, 62%, 60%, 46%, and 80%, respectively. The highest rates were found with relebactam-based combinations, being 76%, 64%, 66%, 76% and 84%, respectively. By contrast, associations with vaborbactam did not lead to significantly increased “non-resistance” rates. Conclusion: Our results showed that all combinations including relebactam led to higher “non-resistance” rates against AmpC-overproducing P. aeruginosa clinical isolates. The best activity was achieved by combining ceftolozane and relebactam, that might therefore be considered as an excellent clinical alternative against AmpC overproducers.


  • Open Access

    Complete genome sequence of the OXA-48-producing Klebsiella pneumoniae strain 11978

    by Otávio Hallal Ferreira Raro, Patrice Nordmann, Laurent Poirel

    We announce the complete genome sequence of Klebsiella pneumoniae strain 11978 isolated from a patient hospitalized in Turkey in 2001. The genome belongs to sequence type 14 and includes three plasmids. Notably, it presents an IncL plasmid carrying bla OXA-48 , which demonstrated global success in terms of dissemination.

  • Open Access

    Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol

    by Otávio Hallal Ferreira Raro, Christophe Le Terrier, Patrice Nordmann, Laurent Poirel

    The impact of chromosomally encoded wild-type or extended-spectrum (ESAC) AmpC β-lactamases of Escherichia coli on susceptibility to ceftazidime, cefepime, and cefiderocol was evaluated in different genetic backgrounds, including wild-type, PBP3-modified, and porin-deficient E. coli strains. Recombinant E. coli strains possessing the different backgrounds and producing variable ESACs were evaluated. Although ESAC enzymes conferred resistance to ceftazidime and decreased susceptibility to cefepime as expected, we showed here that cefiderocol was also a substrate of ESAC enzymes. IMPORTANCE: We showed here that chromosomally encoded intrinsic extended-spectrum cephalosporinases of Escherichia coli may impact susceptibility not only to ceftazidime and cefepime but also to cefiderocol.